Renal Cell Carcinoma Playbook for Urologists: Emerging Strategies Across Lines of Therapy to Optimize Patient Outcomes

Release Date: June 15, 2020
Expiration Date: June 15, 2021

Activity Overview

This online educational activity consists of a series of videos recorded from a live webcast designed to present new clinical data and its implications for the treatment of renal cell carcinoma (RCC) for urology practice. Case scenarios and panel discussions engage a panel of genitourinary specialists in conversations about immunotherapy and targeted therapy approaches to RCC care. Topics include treatment of early-stage and advanced RCC, managing adverse events of targeted and immunotherapy, and current and future strategies for managing RCC.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.

Target Audience

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Explain the biologic rationale for the use of targeted agents and immunotherapies, as single agents and in combination, to treat RCC.
• Evaluate risk stratification criteria, recent clinical trial data, and how emerging adjuvant strategies may further impact the treatment landscape for RCC.
• Review practice-changing and emerging data from clinical trials of systemic therapies for the first-line treatment of metastatic RCC.
• Incorporate knowledge of the safety profiles of systemic therapies with best practices to proactively identify and mitigate treatment-related toxicities during treatment planning for patients with metastatic RCC.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology-Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Grant Research Support: Bristol Myers Squibb, Calithera Biosciences, Exelixis, Merck & Co; Consultant: Apollomics, Arrowhead Pharmaceuticals, Bristol Myers Squibb, Eisai, Merck & Co.

Toni K. Choueiri, MD
Director, The Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
The Jerome and Nancy Kohlberg Chair and Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Analysis Group, AstraZeneca, Alexion Pharmaceuticals, Bayer, Bristol Myers Squibb/ER Squibb & Sons LLC, Calithera Biosciences, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, Exelixis, F. Hoffmann-La Roche, Foundation Medicine Inc., Genentech, GlaxoSmithKline, Ipsen, Lilly, Merck & Co, Novartis, Peloton Therapeutics, Pfizer, Prometheus Labs, Roche, Roche Products Limited, Sanofi/Aventis, Takeda, Tracon Pharmaceuticals; Consultant: Analysis Group, AstraZeneca, Alexion Pharmaceuticals, Bayer, Bristol Myers Squibb/ER Squibb & Sons LLC, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, EMD Serono, Exelixis, Foundation Medicine Inc., Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Lilly, Merck & Co, National Comprehensive Cancer Network, Novartis, Peloton Therapeutics, Pfizer, Prometheus Labs, Roche, Sanofi/Aventis, Up-to-Date; Other: Honoraria: Analysis Group, AstraZeneca, Alexion Pharmaceuticals, Bayer, Bristol Myers Squibb/ER Squibb & Sons LLC, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, EMD Serono, Exelixis, F. Hoffmann-La Roche, Foundation Medicine Inc., Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Lilly, Merck & Co, National Comprehensive Cancer Network, Novartis, Peloton Therapeutics, Pfizer, Prometheus Labs, Roche, Roche Products Limited, Sanofi/Aventis, Up-to-Date.

Daniel J. George, MD
Professor of Medicine and Surgery
Co-Director of the DCI Center for Prostate and Urologic Cancers
Director of GU Oncology
Duke University School of Medicine
Durham, NC

Disclosures: Grant Research Support: Acerta Pharma, Astellas Pharma, Bayer, Bristol Myers Squibb, Calithera Biosciences, Exelixis, Janssen, Novartis, Pfizer, Sanofi; Consultant: Astellas Pharma, Bayer, Bristol Myers Squibb, Exelixis, Flatiron Health, Janssen, Leidos Biomedical, Merck & Co, Myovant Sciences, Pfizer, Sanofi, UroGPO, UroToday; Speakers Bureau: Bayer, Exelixis, Sanofi; Other: Honorarium: EMD Serono, Ipsen.

Christopher G. Wood, MD, FACS
Douglas E. Johnson, MD Endowed Professorship
Professor in Urology
Deputy Chairman, Department of Urology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Argos Therapeutics, CoImmune, Mirati Therapeutics, Pfizer: Researcher; Speakers Bureau: Pfizer; Other: Kidney Cancer Association: Chairman of the Board (No remuneration).

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.